SCHEDULE: Perceptive Advisors Discloses 6.69% Stake in Praxis Precision Medicines
Beneficial Ownership Report
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported a 6.69% beneficial ownership stake in Praxis Precision Medicines, Inc.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. collectively hold 1,362,503 shares of Praxis Precision Medicines, Inc. Common Stock.
- This represents 6.69% of the company's outstanding Common Stock.
- The ownership percentage is based on 20,368,982 shares outstanding as of April 30, 2025, as reported in Praxis Precision Medicines' Form 10-Q filed on May 2, 2025.
- Perceptive Advisors serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd., and Joseph Edelman is the managing member of Perceptive Advisors.
- All reporting persons share both voting and dispositive power over the 1,362,503 shares.
Sentiment
Score: 7
Explanation: The disclosure of a significant beneficial ownership stake by a reputable investment firm like Perceptive Advisors can be viewed positively by the market, suggesting confidence in the company's prospects. While a 13G is a factual filing, the act of taking a substantial position is generally a positive signal.
Positives
- The disclosure of a significant beneficial ownership stake by a reputable investment firm like Perceptive Advisors could be interpreted as a vote of confidence in Praxis Precision Medicines.
Future Outlook
NA
Industry Context
This filing indicates a significant investment by a specialized life sciences fund, Perceptive Advisors, in Praxis Precision Medicines, a company likely operating in the biotechnology or pharmaceutical sector. Such investments by institutional players can signal confidence in the company's pipeline or market position within the broader life sciences industry.
Related Party Transactions
- The filing details the relationship between Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd., where Perceptive Advisors manages the Master Fund and Mr. Edelman is the managing member of Perceptive Advisors. This structure clarifies the shared beneficial ownership.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may influence investor sentiment and potentially the stock price, signaling confidence from a major investor.
- Employees, customers, suppliers, and creditors are not directly impacted by this ownership disclosure.
Key Dates
| Date | Description |
|---|---|
| 2025-04-30 | Date as of which 20,368,982 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-05-02 | Date of filing of the Issuer's Quarterly Report on Form 10-Q, which reported the outstanding shares. |
| 2025-07-15 | Date of event which required the filing of this statement. |
| 2025-07-22 | Date of signing and filing of this Schedule 13G. |
Keywords
Praxis Precision Medicines, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Common Stock, Beneficial Ownership, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.